FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220796557> ?p ?o ?g. }

• W4220796557 endingPage "24" @default.
• W4220796557 startingPage "18" @default.
• W4220796557 abstract "The dose and duration of mesalazine treatment for ulcerative colitis (UC) is a potentially important determinant of effectiveness, with evidence suggesting that continuing the induction dose for 6-12 months may improve outcomes; however, real-world data are lacking. We assessed mesalazine use in Dutch clinical practice, including how differences in dose and duration affected UC outcomes.Adults with mild-to-moderate UC who received oral prolonged-release mesalazine de novo or had a dose escalation for an active episode were followed for 12 months in this non-interventional study (ClinicalTrials.gov identifier: NCT02261636). The primary endpoint was time from start of treatment to dose reduction (TDR). Secondary endpoints included recurrence rate, adherence, and work productivity.In total, 151 patients were enrolled, of whom 108 (71.5%) were newly diagnosed with UC. The majority (120; 79.5%) received a dose of ≥4 g/day. Nearly one-third (48; 31.8%) underwent dose reduction, with mean TDR being 8.3 months. Disease extent and endoscopic appearance did not influence duration of induction therapy, while TDR increased with higher baseline UCDAI scores. TDR was longer in patients without (mean 8.8 months) than with (4.1 months) recurrence, although not significantly (p=0.09). Patients on ≥4 g/day had a significantly lower chance of recurrence versus those on 2-<4 g/day (26.6% vs 62.5%, respectively; p=0.04). Longer treatment duration was associated with significantly reduced recurrence risk [hazard ratio >6 months vs 3-6 months: 0.19 (95%CI: 0.08-0.46); p<0.05], particularly for those on ≥4 g/day [0.15 (0.06-0.40) vs 0.26 (0.01-11.9) for 2-<4 g/day). Patients reported significantly increased work productivity, which was maintained throughout follow-up.Mesalazine was effective induction therapy, with treatment duration not meaningfully influenced by disease extent and endoscopic appearance at initiation. A higher induction dose of oral mesalazine (≥4 g/day) and longer duration of treatment (>6 months) was associated with a lower recurrence risk." @default.
• W4220796557 created "2022-04-03" @default.
• W4220796557 creator A5000656463 @default.
• W4220796557 creator A5003213570 @default.
• W4220796557 creator A5010796219 @default.
• W4220796557 creator A5013415442 @default.
• W4220796557 creator A5017828484 @default.
• W4220796557 creator A5021806501 @default.
• W4220796557 creator A5032569427 @default.
• W4220796557 creator A5033279901 @default.
• W4220796557 creator A5035206417 @default.
• W4220796557 creator A5037821832 @default.
• W4220796557 creator A5037880873 @default.
• W4220796557 creator A5038737152 @default.
• W4220796557 creator A5047324292 @default.
• W4220796557 creator A5050614817 @default.
• W4220796557 creator A5052933254 @default.
• W4220796557 creator A5055923700 @default.
• W4220796557 creator A5090437455 @default.
• W4220796557 creator A5090478094 @default.
• W4220796557 date "2022-03-19" @default.
• W4220796557 modified "2023-10-02" @default.
• W4220796557 title "Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study" @default.
• W4220796557 doi "https://doi.org/10.15403/jgld-3927" @default.
• W4220796557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35306553" @default.
• W4220796557 hasPublicationYear "2022" @default.
• W4220796557 type Work @default.
• W4220796557 citedByCount "1" @default.
• W4220796557 countsByYear W42207965572023 @default.
• W4220796557 crossrefType "journal-article" @default.
• W4220796557 hasAuthorship W4220796557A5000656463 @default.
• W4220796557 hasAuthorship W4220796557A5003213570 @default.
• W4220796557 hasAuthorship W4220796557A5010796219 @default.
• W4220796557 hasAuthorship W4220796557A5013415442 @default.
• W4220796557 hasAuthorship W4220796557A5017828484 @default.
• W4220796557 hasAuthorship W4220796557A5021806501 @default.
• W4220796557 hasAuthorship W4220796557A5032569427 @default.
• W4220796557 hasAuthorship W4220796557A5033279901 @default.
• W4220796557 hasAuthorship W4220796557A5035206417 @default.
• W4220796557 hasAuthorship W4220796557A5037821832 @default.
• W4220796557 hasAuthorship W4220796557A5037880873 @default.
• W4220796557 hasAuthorship W4220796557A5038737152 @default.
• W4220796557 hasAuthorship W4220796557A5047324292 @default.
• W4220796557 hasAuthorship W4220796557A5050614817 @default.
• W4220796557 hasAuthorship W4220796557A5052933254 @default.
• W4220796557 hasAuthorship W4220796557A5055923700 @default.
• W4220796557 hasAuthorship W4220796557A5090437455 @default.
• W4220796557 hasAuthorship W4220796557A5090478094 @default.
• W4220796557 hasBestOaLocation W42207965571 @default.
• W4220796557 hasConcept C126322002 @default.
• W4220796557 hasConcept C141071460 @default.
• W4220796557 hasConcept C168563851 @default.
• W4220796557 hasConcept C203092338 @default.
• W4220796557 hasConcept C207103383 @default.
• W4220796557 hasConcept C2779134260 @default.
• W4220796557 hasConcept C2779174533 @default.
• W4220796557 hasConcept C2780479503 @default.
• W4220796557 hasConcept C44249647 @default.
• W4220796557 hasConcept C71924100 @default.
• W4220796557 hasConcept C90924648 @default.
• W4220796557 hasConceptScore W4220796557C126322002 @default.
• W4220796557 hasConceptScore W4220796557C141071460 @default.
• W4220796557 hasConceptScore W4220796557C168563851 @default.
• W4220796557 hasConceptScore W4220796557C203092338 @default.
• W4220796557 hasConceptScore W4220796557C207103383 @default.
• W4220796557 hasConceptScore W4220796557C2779134260 @default.
• W4220796557 hasConceptScore W4220796557C2779174533 @default.
• W4220796557 hasConceptScore W4220796557C2780479503 @default.
• W4220796557 hasConceptScore W4220796557C44249647 @default.
• W4220796557 hasConceptScore W4220796557C71924100 @default.
• W4220796557 hasConceptScore W4220796557C90924648 @default.
• W4220796557 hasIssue "1" @default.
• W4220796557 hasLocation W42207965571 @default.
• W4220796557 hasLocation W42207965572 @default.
• W4220796557 hasLocation W42207965573 @default.
• W4220796557 hasOpenAccess W4220796557 @default.
• W4220796557 hasPrimaryLocation W42207965571 @default.
• W4220796557 hasRelatedWork W1506122018 @default.
• W4220796557 hasRelatedWork W2078745520 @default.
• W4220796557 hasRelatedWork W2263605371 @default.
• W4220796557 hasRelatedWork W2352254143 @default.
• W4220796557 hasRelatedWork W2355129079 @default.
• W4220796557 hasRelatedWork W2382465907 @default.
• W4220796557 hasRelatedWork W2386497540 @default.
• W4220796557 hasRelatedWork W2407927805 @default.
• W4220796557 hasRelatedWork W3032188930 @default.
• W4220796557 hasRelatedWork W4321748671 @default.
• W4220796557 hasVolume "31" @default.
• W4220796557 isParatext "false" @default.
• W4220796557 isRetracted "false" @default.
• W4220796557 workType "article" @default.